CoChat

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Valle, Juan W., Armstrong, Anne, Newman, Chris, Alakhov, Valery, Pietrzynski, Grzegorz, Brewer, Julie, Campbell, Sue, Corrie, Pippa, Rowinsky, Eric K., Ranson, Malcolm · 2011 · Investigational New Drugs

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Purpose To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction (GEJ). Patients and methods Patients with metastatic or locally advanced unresectable adenocarcinoma of the esophagus or GEJ who had not previously received systemic chemotherapy and had measurable disease were treated with SP1049C 75 mg/m(2) (doxorubicin equivalents) as a brief intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was the objective response rate in patients who had received a least one course of SP1049C and had undergone tumor assessment, whereas, secondary endpoints included the objective response rate, progression-free survival (PFS), overall survival, and safety in the intent-to-treat (ITT) population. A review of scans was also conducted post-hoc by a blinded panel of radiologists. Results Twenty-one patients, of which 19 were evaluable for response, were treated with at least one dose of SP1049C. Nine patients had a partial response (PR) and eight patients had either a minor response or stable disease as their best response. The objective response rate was 47% (95% CI: 24.4-71) in the evaluable patient population, whereas the objective response rate was 43% (95% CI: 21.8-65.9) in the ITT population. The post-hoc radiol…

Overview

Integrity signals

Registry

Crossref · 10.1007/s10637-010-9399-1

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 45 references

Cited by

See all 311

Metadata

Authors
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M.
Affiliations
  • The Christie Hospital (GB)
  • Supratek Pharma (Canada) (CA)
  • Addenbrooke's Hospital (GB)
  • University of Manchester (GB)
Corresponding author
Valle, Juan W.
Venue
Investigational New Drugs
Published
2010-02-24
Volume
29
Issue
5
Pages
1029-1037
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W1964185052
Cited by
303
References
45
Citations by year
2026: 8 · 2025: 4 · 2024: 11 · 2023: 14 · 2022: 20 · 2021: 10 · 2020: 29 · 2019: 23 · 2018: 22 · 2017: 23 · 2016: 35 · 2015: 29 · 2014: 23 · 2013: 26 · 2012: 12
FWCI
17.63
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Investigational New Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
doxorubicin, P-glycoprotein, poloxamer, micellar drug delivery, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, advanced adenocarcinoma, objective response rate, progression-free survival, overall survival, neutropenia, cardiotoxicity, anticancer activity
MeSH terms
Adenocarcinoma, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Doxorubicin, Esophageal Neoplasms, Esophagogastric Junction, Female, Humans, Male, Middle Aged, Neoplasm Staging, Stroke Volume, ATP Binding Cassette Transporter, Subfamily B, Member 1, Poloxamer, Kaplan-Meier Estimate, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. https://app.cochat.ai/papers/10.1007/s10637-010-9399-1
The paper
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011). A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investigational New Drugs. https://doi.org/10.1007/s10637-010-9399-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.